Option Compounds definition

Option Compounds means [* * *] Antibodies, [* * *] Antibodies, and [* * *] Antibodies.
Sample 1Sample 2Sample 3
Option Compounds means any compound (a) that is not (i) a Licensed Compound hereunder or (ii) a “Licensed Compound,” “Licensed Product,” or “Option Compound” under the ACE-011 Agreement, (b) that is Controlled by Acceleron, and (c) for which Acceleron has submitted an IND (which is accepted by the applicable Regulatory Authority) for Use in Anemia; provided that, notwithstanding anything to the contrary in this Agreement, Acceleron shall not be deemed to Control any additional Option Compounds following a Change of Control of Acceleron that were not Controlled by Acceleron prior to such Change of Control.
Sample 1Sample 2Sample 3
Option Compounds means any compound (a) that is not (i) a Licensed Compound hereunder or (ii) a “Licensed Compound,” “Licensed Product,” or “Option Compound” under the ACE-011 Agreement, (b) that is Controlled by Acceleron, and(c) for which Acceleron has submitted an IND (which is accepted by the applicable Regulatory Authority) for Use in Anemia; provided that, notwithstanding anything to the contrary in this Agreement, Acceleron shall not be deemed to Control any additional Option Compounds following a Change of Control of Acceleron that were not Controlled by Acceleron prior to such Change of Control.
Sample 1Sample 2

Examples of Option Compounds in a sentence

  • During the Option Term, but subject to Section 7.3, Acceleron may develop, through the filing of an IND, compounds that are to become Option Compounds; provided that Acceleron shall provide Celgene prompt written notice of any compound becoming an Option Compound by virtue of Acceleron filing an IND (which is accepted by the applicable Regulatory Authority) for such compound for Use in Anemia.

  • As soon as practicable after the exercise by GSK of a Program Option for a Program and receipt from Regulus of the information and materials set forth in Sections 5.3.1 and 5.3.2, GSK shall promptly commence and pursue a program of ongoing Development and Commercialization for the Option Compounds under such Program, in accordance with GSK’s diligence obligations set forth below.

  • Myers included his own observation that Malone was the only officer who did not shoot at the first target during the shotgun qualification on May 28 and that she seemed unable to figure out why her shotgun would not shoot.

  • For the purposes of this Section 1.77, the definition of each of “Development Costs” and “Development” shall be deemed to apply to Option Compounds mutatis mutandis as it applies to Licensed Compounds and Licensed Products (i.e., substituting “Option Compounds” for “Licensed Compounds” or “Licensed Products”).

  • The price for supply by ChemoCentryx of excess quantities of such preclinical supply or clinical supply of Collaboration Compounds, Development Candidates or Option Compounds shall be the [***].

  • The forecast of price, quantity, schedule, and specifications for supply of Collaboration Compounds, Development Candidates, or Option Compounds under this Section 3.14 shall be mutually coordinated through the JPS and shall be consistent with the Product Candidate Commercialization Program; provided, however, that the forecast shall be non-binding and operative only for planning purposes, and neither Party shall have any contractual obligation with respect thereto.

  • Other than the trademarks described above which are owned by Regulus prior to the exercise of a Program Option by GSK, the Commercializing Party shall be solely responsible for developing, selecting, searching, registration and maintenance of, and shall be the exclusive owner of all trademark(s), trade dress, logos, slogans, designs, copyrights and domain names used on and/or in connection with any of the Option Compounds and Licensed Products resulting from a Program.

  • The common objective of the Parties is to identify and develop at least four (4) and up to a maximum of six (6) Option Compounds (and their Back-Up Compounds) for Development and commercialization in the Territory under the terms of this Agreement.

  • GSK understands that the Collaboration Compounds are the subject of ongoing clinical research and development and that ChemoCentryx cannot assure the safety or usefulness of resulting Development Candidates, Option Compounds, and/or Licensed Products.

  • For purposes of clarity, this Section 6.6.1(d)(4) shall not apply in the event of sale of Terminated Compounds (including Terminated AZ Compounds), Unexercised Option Compounds or any product to the extent that it contains a Terminated Compound (including a Terminated AZ Compound) or Unexercised Option Compound.


More Definitions of Option Compounds

Option Compounds means any compound Controlled by ACADIA as of the Effective Date the primary mode of action of which is activity as a selective inverse agonist of 5HT2A[...***...]. Notwithstanding the foregoing or any other provision of this Agreement to the contrary, ACADIA’s compound known as ACP-103 shall not be considered an Option Compound for purposes of this Agreement.
Sample 1
Option Compounds means any compound developed by AEZS or its Affiliates to reach the same target in human cells as any Licensed Compound, by using a different structure to any Licensed Compound, but excluding the Licensed Compounds.
Sample 1
Option Compounds means any compound Controlled by ACADIA as of the Effective Date the primary mode of action of which is activity as a selective inverse agonist of 5HT2A[...
Sample 1
Option Compounds means any compound developed by Pharmacyclics prior or during the Research Term:
Sample 1

Related to Option Compounds

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Licensed Compound means (a) 3,4-Diaminopyridine, the chemical structure of which is set forth on Exhibit B-2; and (b) any derivatives, isomers, metabolites, prodrugs, acid forms, base forms, salt forms, or modified versions of such compound in (a).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Compounds means a small molecule HMT inhibitor.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Development rights means any right or combination of rights reserved by a declarant in the declaration to:

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Nicotine product means a product that contains nicotine and is not any of the following:

  • Diagnostic Product means In Vitro Diagnostics, In Vivo Diagnostic Agents and any product used for Diagnosis.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • New Product means the Synology-branded hardware product and Synology-branded accessories contained in the original packaging Customer bought from an authorized Synology distributor or reseller. You may see our “New Product” at Product Support Status.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Commercialise means to promote, market, distribute and/or sell a Product and “Commercialising” and “Commercialisation” shall be construed accordingly;

  • Hemp product means the same as that term is defined in § 3.2-4112.

  • Drug Substance means an active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient.

  • New Products means any product which is not an Enhanced Product or 2 Existing Product but which is substantially similar to an Existing Product with respect to design and function and possesses reasonable performance improvements. If Company desires to purchase an Enhanced or New Product(s) from Supplier, Company shall so notify Supplier and provide Supplier the opportunity to manufacture such Enhanced or New Product(s), subject to the following conditions and procedures.

  • Hemp products means all products made from industrial hemp,

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Exempt compound means the same as defined in Rule 2.

  • Licensed Product means any method, process, composition, product, service, or component part thereof that would, but for the granting of the rights set forth in this Agreement, infringe a Valid Claim contained in the Licensed Patents.

  • Drug Product means a specific drug in dosage form from a known source of manufacture, whether

  • Gene Therapy means the introduction of a nucleic acid sequence encoding a protein intended for or otherwise conferring therapeutic benefit into a person for therapeutic purposes (i) by in vivo introduction for incorporation into cells of such person, or (ii) by ex vivo introduction into cells for transfer into a person.

  • Licensed Products means tangible materials which, in the course of manufacture, use, sale, or importation, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.